Nina Bhardwaj, MD, PhD
Icahn School of Medicine at Mount Sinai
8
7
4
N/A
0
7
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+3 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (8)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Kevin Staveley-O'Carroll, MD
University Missouri
Shared therapeutic areas:
Worked with same sponsors:
Frederick P Smith, MD
Chevy Chase, RCCA
Shared therapeutic areas:
Worked with same sponsors:
David H Smith, MD
Bay Hematology Oncology
Shared therapeutic areas:
Worked with same sponsors:
Marina Kremyanskaya, MD, PhD
Icahn School of Medicine at Mount Sinai
Shared therapeutic areas:
Worked with same sponsors:
Camelia Iancu-Rubin, PhD
Icahn School of Medicine at Mount Sinai
Shared therapeutic areas:
Worked with same sponsors:
Rachel Sabado, PhD
Icahn School of Medicine at Mount Sinai
Shared therapeutic areas:
Worked with same sponsors:
Frederick P Smith, MD
Chevy Chase Healthcare
Shared therapeutic areas:
Worked with same sponsors:
David H Smith, MD
Bay Hematology Oncology PA
Shared therapeutic areas:
Worked with same sponsors:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
E-mail: ClinicalTrials@ ImClone.com
Eli Lilly and Company
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (8)
Showing 8 of 8 trials
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1
Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)
A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence
Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®
Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies
All 8 trials loaded